雪榕生物(300511) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥568,629,537.95, representing a decrease of 15.86% compared to the same period last year[5] - The net profit attributable to shareholders was -¥169,152,861.04, a decline of 258.02% year-on-year[5] - Total operating revenue for the third quarter reached ¥1,943,485,303.98, an increase of 17.8% compared to ¥1,649,344,357.67 in the same period last year[26] - The net loss for Q3 2023 was CNY 126.71 million, compared to a net loss of CNY 7.02 million in the same period last year, indicating a significant increase in losses[27] - The company reported a total comprehensive loss of CNY 126.10 million for Q3 2023, compared to a loss of CNY 8.31 million in Q3 2022[27] - Operating profit for the period was a loss of ¥125,380,584.81, compared to a loss of ¥13,568,694.10 in the previous year[26] Cash Flow - The cash flow from operating activities showed a net inflow of ¥215,734,213.51, an increase of 22.33% compared to the previous year[5] - The operating cash flow for Q3 2023 was CNY 215.73 million, up from CNY 176.35 million in Q3 2022, reflecting a growth of approximately 22%[28] - The cash flow from investing activities for Q3 2023 was negative at CNY -486.25 million, compared to a negative cash flow of CNY -368.62 million in Q3 2022[29] - The cash flow from financing activities generated a net inflow of CNY 346.17 million in Q3 2023, compared to CNY 313.83 million in Q3 2022[29] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,529,390,973.75, reflecting an increase of 11.23% from the end of the previous year[5] - Current assets totaled ¥1,027,268,382.14, a decrease of 13.8% from ¥1,192,555,284.59 at the beginning of the year[24] - Non-current assets increased to ¥3,502,122,591.61, up 21.6% from ¥2,879,476,786.76 at the start of the year[24] - Total liabilities reached ¥2,975,866,433.49, an increase of 21.6% compared to ¥2,446,198,711.98 at the beginning of the year[24] - Total equity attributable to shareholders decreased to ¥1,669,132,732.64, down 4.3% from ¥1,743,262,805.16[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37.135 million[16] - The largest shareholder, Yang Yongping, holds 21.57% of shares, totaling 107,606,850 shares[16] - The top ten shareholders hold a combined total of 56.83% of the company's shares[16] - The total number of restricted shares at the end of the period is 90,543,144 shares, with no shares released during the reporting period[19] - The company has no known related party relationships or concerted action among other shareholders[17] Investments and Projects - The company plans to invest over RMB 1.2 billion in the modern agricultural industrial park project in Guigang City, increasing the total investment from over RMB 650 million[21] - The company established a wholly-owned subsidiary, Guangxi Xuerong Biotechnology Co., Ltd., with a registered capital of RMB 100 million[20] - The company has signed an investment agreement with the local government for the construction of the industrial park project[20] Other Financial Metrics - The weighted average return on equity was -9.71%, a decrease of 15.04% compared to the previous year[5] - The company experienced a 91.17% decrease in investment income, amounting to ¥1,255,499.49, attributed to reduced cash management returns[12] - Sales expenses surged by 405.20% to ¥73,617,755.24, primarily due to increased investment in brand building and channel promotion[12] - The company reported a decrease in government subsidies recognized as other income, which fell by 52.47% to ¥6,500,819.36[12] - The company experienced a decrease in other comprehensive income, with a net amount of CNY 608,185.45 in Q3 2023, compared to a loss of CNY 1.30 million in Q3 2022[27] Audit and Reporting - The company’s financial report for Q3 2023 is pending release, with the balance sheet as of September 30, 2023, yet to be detailed[22] - The company has not undergone an audit for the Q3 2023 report[30]